Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ventilator-associated pneumonia), complicated intra-abdominal and urinary tract infections.

Doripenem is a carbapenem with a broad spectrum of activity. It inhibits bacterial cell wall biosynthesis and is indicated for the treatment of serious infections in secondary care.

Doripenem is given by infusion over one to four hours every eight hours. The longer infusion period should be considered when the infection is caused by less susceptible pathogens; extending the infusion time maximises the period when the plasma concentration exceeds the minimum inhibitory concentration.

Species resistant to other carbapenems do generally express co-resistance to doripenem.

View Doribax drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...